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Abstract 
There is no effective treatment for advanced extramammary Paget’s disease (EMPD). The 
human epidermal growth factor receptor 2 (HER2) protein is often overexpressed in EMPD. 
Trastuzumab is a humanized monoclonal antibody against HER2 used in the treatment of 
breast cancers in which HER2 is overexpressed. We report a case of advanced EMPD in 
which trastuzumab and paclitaxel combination therapy was effective. The patient was a 
70-year-old Japanese woman who presented with EMPD on the vulva and multiple 
metastatic lymph nodes. Immunohistochemical staining revealed strong HER2 protein 
expression in the primary tumor and metastatic lymph nodes. The patient received 
trastuzumab and paclitaxel. After 4 courses of this regimen, the mass on the vulva and the 
metastatic lymph nodes regressed. Our findings may imply that trastuzumab plus paclitaxel 
combination therapy is useful for the treatment of advanced EMPD overexpressing HER2. 
 
Introduction 
Extramammary Paget’s disease (EMPD) is a relatively rare malignant skin tumor 
which is considered to originate from cutaneous appendages and occurs in cutaneous 
areas bearing apocrine glands, such as the scrotum, vulva, and axilla. Generally, its 
prognosis is favorable if the primary lesion is completely resected and no metastases 
are present. However, the prognosis of the progressive disease is poor because there is 
currently no effective treatment for advanced EMPD. Case Rep Dermatol 2011;3:223–227 
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Trastuzumab (Herceptin ; Genentech, Inc., San Francisco, Calif., USA) is a humanized 
monoclonal antibody which selectively targets human epidermal growth factor 
receptor 2 (HER2) and is approved for the treatment of metastatic breast cancer (MBC). 
Trastuzumab used in combination with paclitaxel is the first-line chemotherapy for 
HER2-overexpressing MBC, with a response rate of 56–84% [1, 2]. Similarly, the HER2 
protein is sometimes overexpressed in EMPD, and in such cases trastuzumab plus 
paclitaxel combination therapy is also expected to be effective. 
We describe a case of advanced EMPD in which the primary tumor mass and lymph 
node metastasis regressed with combined trastuzumab and paclitaxel therapy. Our 
observation may imply that this combination therapy is effective for advanced EMPD 
with HER2 overexpression. 
Case Report 
A 70-year-old Japanese woman presented with a 10-year history of an asymptomatic erythema on 
the vulva, which had gradually increased in size. She was referred to our hospital in October 2008. 
Physical examination revealed a 10 × 13 cm, slightly raised erythematous lesion with ulcers and a 
hemorrhagic granulomatous lesion (fig. 1). Left inguinal lymphadenopathy (3 cm in size) was present, 
but without tenderness. Computed tomography (CT) and positron emission tomography revealed 
multiple lymph node swelling in the pararenal artery lymph node, the left inguinal lymph node and 
the subclavian axillary lymph node. Histological examination of biopsy specimens taken from the 
genital area and left inguinal lymph node showed atypical tumor cells with an abundant pale-staining 
cytoplasm and large atypical nuclei (fig. 2a). On the basis of these findings, we made a diagnosis of 
advanced EMPD. Immunohistochemical staining showed that the Paget’s cells stained strongly for the 
Her2 protein (fig. 2b). The role of the HER2 signal pathway in EMPD was assessed. Epidermal growth 
factors bind to HER2 receptors, and this signal is transduced into the phosphatidylinositol 3 kinase 
and extracellular signal-regulated kinase (ERK) pathways by phosphorylation of AKT (pAKT) and ERK 
(pERK). Activation of pAKT and pERK is considered to be a hallmark of the activation of these signal 
transduction pathways [3]. Immunohistochemical staining of the biopsy specimens of the primary 
tumor revealed that Paget’s cells were positive for both pAKT and pERK (fig. 2c, d). 
These results suggested that trastuzumab might be effective for the present HER2-overexpressing 
EMPD case. Therefore, we initially decided to treat this patient with trastuzumab. After gaining the 
informed consent of the patient, we administered trastuzumab at a loading dose of 4 mg/kg 
intravenously. After the first dose, a weekly 2-mg/kg maintenance dose was administered for 
5 weeks. However, there was no objective response. We then treated the patient with weekly 
trastuzumab (2 mg/kg) in combination with paclitaxel (80 mg/kg). This combination therapy was 
administered weekly for 6 weeks followed by a 2-week rest according to a protocol for HER2-positive 
MBC. After 4 courses of this therapy, the granulomatous lesion on the vulva had disappeared (fig. 1b). 
A CT scan also revealed the regression of the pararenal artery lymph node metastasis (fig. 3). 
Histopathologically, most of the tumor cells in the epidermal nest and lymph nodes had disappeared. 
Similarly, almost no Paget’s cells overexpressing the HER2 protein could be identified (fig. 2f). After 
6 courses, we stopped the combination therapy because the patient developed grade 3 neutrophilic 
leukopenia. In December 2009, a remarkable edema of the left leg appeared, and enlargement of the 
left inguinal lymph nodes was detected by CT. Since then, the patient has been treated with local 
irradiation for both the inguinal lymph nodes and the primary lesion. 
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Discussion 
The prognosis of advanced EMPD is extremely poor, and there is currently no 
effective treatment for this condition. Several studies have shown frequent 
amplification of the HER2 gene and overexpression of the HER2 protein in patients with 
EMPD. It has been reported that 20–60% of EMPD patients express the HER2 protein 
[4–7]. Trastuzumab, a humanized monoclonal antibody against HER2, has found to be 
useful in treating MBC. Targeted treatment of HER2-positive MBC with single-agent 
trastuzumab demonstrates favorable efficacy, and this efficacy is enhanced by the 
combination with paclitaxel [1, 2, 8, 9]. Therefore, combination treatment with 
trastuzumab and paclitaxel is used as a first-line standard therapy for HER2-positive 
MBC. 
In our case, the patient had multiple lymph node metastases, and we had considered 
her as inoperable. Both the primary site and the metastatic lymph nodes expressed the 
HER2 protein, pAKT and pERK, as determined by immunohistochemical staining (fig. 
2b–d). Activation of pAKT and pERK is a hallmark of the activation of HER2 signal 
transduction pathways. Ogawa et al. [3], using immunohistochemical staining, reported 
that some cases of EMPD presented with overexpression of the HER2 protein, pAKT 
and pERK. They showed that pAKT was detected in 75.0% and pERK in 38.9% of EMPD 
patients. Both the phosphatidylinositol 3 kinase and the ERK pathways appear to be 
involved in the progression of EMPD. It has been postulated that antibody-dependent 
cellular cytotoxicity may play an important role in the mechanism of action of 
trastuzumab [10]. On the other hand, trastuzumab binds to the surfaces of HER2-
overexpressing cancer cells and inhibits downstream signaling via pAKT and pERK. In 
our case, after combination therapy with trastuzumab and paclitaxel, the expressions of 
the HER2 protein, pAKT and pERK in EMPD were decreased (fig. 2f–h). These results 
may imply that paclitaxel plus trastuzumab combination therapy selectively targets the 
tumor cells with high HER2 expression or that it decreased the signal transduction of 
HER2. 
In this particular case, the combination therapy with trastuzumab and paclitaxel, the 
standard first-line chemotherapy for MBC, was effective for progressive-stage EMPD 
with HER2 overexpression. Our observations may suggest that this therapy should be 
considered as an option for the treatment of HER2-positive EMPD. 
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Fig. 1. a A granulomatous lesion with ulcers on the vulva. b A scar on the vulva after 6 courses of 
paclitaxel plus trastuzumab combination therapy. 
 
 
 
Fig. 2. Microscopic examination revealed numerous nests of Paget’s cells in the epidermis before the 
therapy (a); however, the number of these cells decreased after the therapy (e). HE stain; original 
magnification, ×100. Representative results for the immunohistochemical examination of HER2, pAKT 
and pERK before (b–d) and after (f–h) the therapy. 
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Fig. 3. a A swollen pararenal artery lymph node identified using CT. b Apparent regression of the 
metastatic lesion in the lymph node after trastuzumab plus paclitaxel administration. Circles indicate 
lymph nodes. 
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